Medical cannabis white paper released as Australia moves towards legalisation
Published 22-SEP-2016 09:44 A.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharmaceuticals has been collaborating with the University of Sydney Business School community engagement program in the production of a medical cannabis white paper.
The paper, titled Clinical Evidence for Medical Cannabis: Epilepsy, Cancer and Multiple Sclerosis examines existing evidence supporting the efficacy of medical cannabis.
This second collaboration between the two also examines medical cannabis applicability to relieve associated symptoms for a range of health related issues, including pain nausea and loss of appetite.
For medical cannabis to become a trusted treatment option among medical professionals and patients alike, there needs to be rigorous clinical evidence supporting efficacy,” said MGC co-founder and managing director Nativ Segev.
“We believe in the potential of medical cannabis more than most, but that belief needs to be proven in the lab under strict conditions.”
MGC has provided support and expertise developed in the Israeli medical cannabis industry to the University of Sydney during the study, giving insight into the broader industry.
Of course this is still an early stage company and its expertise is some way off morphing into profitability, so if considering MGC as an investment, seek professional financial advice.
MGC is also in further discussions with leading Australian institutions to provide support and expertise, as they “strive to increase our understanding of the benefits of medical cannabis and its potential uses as a safe and effective treatment option,” Segev concluded.
Co-ordinator of the study Michael Katz of the University of Sydney believes Australia has made great strides in medical cannabis advancement.
“Australia has made great advances in paving the way for medical cannabis to be available as a treatment option, but we now need to undertake more research to understand exactly how and why it can be used effectively with patients.”
Certainly governments are taking a broader view of the industry.
In July this year, the NSW government was given approval to grow cannabis under licence from the federal government as part of research into the best way to cultivate the plant.
According to the NSW state government, this move lays the foundations for private growers to supply medical marijuana.
“This underpins the potential pharmaceutical supply of cannabis-based medicines made in Australia,” said the NSW Primary Industries Minister, Niall Blair. “We are the first state to be authorised by the Commonwealth to conduct cultivation research.”
The move comes as medicinal cannabis will become legal, but strictly controlled from November this year, under a formal decision reached by the Therapeutic Goods Administration in early September.
Earlier in the year, the Federal Parliament lent bipartisan support to changes to the Narcotic Drugs Act to allow cannabis to be legally grown and produced in Australia for medicinal purposes as part of a national scheme.
NB: The new White Paper can be found here.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
